{"filing":{"accession_number":"0001654954-26-007050","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"a7288o.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007050/a7288o.htm"},"events":[{"id":22899,"run_id":20735,"accession_number":"0001654954-26-007050","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This 6-K discloses European Commission approval of Datroway (datopotamab deruxtecan) for first-line treatment of metastatic triple-negative breast cancer, a significant regulatory milestone for AstraZeneca's oncology portfolio. The approval is based on positive Phase III trial results (TROPION-Breast02) showing statistically significant overall survival and progression-free survival benefits. While not a discrete M\u0026A transaction, earnings release, or executive change, this regulatory approval of a marketed pharmaceutical product represents a material operational and commercial milestone that would affect a reasonable investor's assessment of the company's pipeline progress and market opportunities in oncology.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":22994,"accession_number":"0001654954-26-007050","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This 6-K discloses European Commission approval of Datroway (datopotamab deruxtecan) for first-line treatment of metastatic triple-negative breast cancer, a significant regulatory milestone for AstraZeneca's oncology portfolio. The approval is based on positive Phase III trial results (TROPION-Breast02) showing statistically significant overall survival and progression-free survival benefits. While not a discrete M\u0026A transaction, earnings release, or executive change, this regulatory approval of a marketed pharmaceutical product represents a material operational and commercial milestone that would affect a reasonable investor's assessment of the company's pipeline progress and market opportunities in oncology.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:38:11.132017+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-07-31"}]}